Amgen Inc. $AMGN Shares Acquired by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 7.0% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 64,628 shares of the medical research company’s stock after buying an additional 4,201 shares during the quarter. Amgen accounts for about 1.5% of China Universal Asset Management Co. Ltd.’s investment portfolio, making the stock its 10th largest position. China Universal Asset Management Co. Ltd.’s holdings in Amgen were worth $18,238,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of AMGN. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares during the period. Sivia Capital Partners LLC increased its position in shares of Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the period. Schnieders Capital Management LLC. raised its stake in shares of Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Retirement Planning Group LLC lifted its position in Amgen by 1.4% in the second quarter. Retirement Planning Group LLC now owns 2,752 shares of the medical research company’s stock worth $768,000 after purchasing an additional 39 shares during the period. Finally, Onyx Bridge Wealth Group LLC boosted its stake in Amgen by 7.6% during the second quarter. Onyx Bridge Wealth Group LLC now owns 1,538 shares of the medical research company’s stock worth $429,000 after buying an additional 108 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HSBC reaffirmed a “buy” rating and set a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. Barclays set a $185.00 price objective on Amgen in a report on Thursday. Scotiabank assumed coverage on Amgen in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 target price for the company. The Goldman Sachs Group upped their price target on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. Finally, Daiwa Securities Group lifted their price objective on Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $345.16.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $375.50 on Friday. The business has a fifty day moving average of $342.07 and a 200-day moving average of $315.70. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12. The firm has a market cap of $202.42 billion, a PE ratio of 26.39, a price-to-earnings-growth ratio of 3.89 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter last year, the company posted $5.31 EPS. The company’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s dividend payout ratio (DPR) is currently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.